Member Info for SGD27

Perhaps when it's commercialised it could be supplied as an e-cigarette cartridge :-)

@Forest24 : It's also interesting that the nebuliser demonstrated is clearly for inhalation via the mouth, whereas here

https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/281317/

it says "SNG001 is an inhaled form (one that is breathed in through the nose) ..."

I'm not sure how much it matters, although there is research suggesting that the nose is the most covid-infectable location in the respiratory tract :

https://www.cell.com/cell/fulltext/S0092-8674(20)30675-9

Thanks blaustein, that's more detailed coverage than the version we had earlier today.

(BTW It starts at ~08:00 for anyone searching through.)

Forgot to say: well spotted Sheephatch :-)

At 07:15 :

https://www.bbc.co.uk/iplayer/episode/m000jl5v/south-today-lunchtime-news-28052020

Listening to the Proactive interview makes one realise just how much infrastructure is involved in the home-based trial. I think they've to be congratulated on getting it up and running so quickly.

https://www.youtube.com/watch?v=vVUrk7DemKE

@hinumaki : Of course missing target dates always looks bad. But I think it's been out of their control - a problem with recruitment numbers: (a) falling numbers of hospitalised patients (b) competition from the myriad of other trials (c) tightening the criteria by trying to concentrate on early treatment.

The alternative would have been to meet the deadlines by loosening the entry criteria. I doubt if anyone here thinks that would have been a good idea.

BTW Just in case I'm being misunderstood, I think the 'crit' in 'emcrit' refers to the neutral, not pejorative, definition of the word 'criticism'.

Not sure about "won't be required" - they'll review it if they feel like it! They did an interesting review of the Wang et al remdesivir trial which was randomised, double-blind & placebo-controlled (but stopped early) :

https://emcrit.org/pulmcrit/wang-remdesivir/

If anyone's looking for a bit of bank holiday background reading, then I recommend this site :

https://emcrit.org/

in which qualified people critically review recent medical publications. The two most recent reviews are of the latest remdesivir ACTT-1 trial report, and they have a bit of a go at what has been left out, even using the word "censoring"!

I wonder if they will do a review of our trial results when they're published?

This is a closely related US study, just picked up by 'pdt' on ad vfn :

https://www.biorxiv.org/content/10.1101/2020.05.19.105437v1

It's reached the DM!

https://www.dailymail.co.uk/health/article-8344997/How-coronavirus-hijacks-human-cells-takes-genes-turns-immune-against-us.html

An MOU is certainly not a guarantee of a customer. However, they've invested a lot of time, effort & money looking at our product, and have come back with positive comments, so I think there's good reason for optimism.

This is just one for the very keen researchers (nobbygnome, are you there?), it's very technical!

They're studying IFN-alpha not beta but (if I understand correctly) they find that it can lead to opposite effects, depending on the details of timing.

https://www.biorxiv.org/content/10.1101/2020.05.18.103101v1

"... our results, highlighting the importance of IFN dynamics, may suggest time-based strategies for enhancing the effectiveness of IFN pretreatment in clinical applications against viruses, such as SARS-CoV-2."

"Latest research revealed that SARS-CoV28 2 is especially sensitive to type I IFNs, compared to other coronaviruses, making IFN pretreatment a potential strategy to prevent SARS-CoV-2 infection [43-45]. Our findings suggested possible ways to enhance the effectiveness of IFNs for future clinical use. For example, repetitive short-term administrations of IFN may lead to less desensitization and a more dramatic effect than prolonged treatments."

AGEOS, you say "industry is still in early R & D phase regarding use of the material"

- but it's been in use for two millennia!!

Seriously though, many thanks for that very detailed reply. Sounds like even if NSH turns out to be viable, they'd be a good year or two behind us.

This is just out, but relates to the recent Wuhan IFN-alpha2B study which has been mentioned here several times :

https://www.reuters.com/article/covid19-ifna2b/interferon-therapy-may-speed-recovery-from-covid-19-idUSL1N2D20Z0

I found this bit reassuring :

"
Dr. Fish noted that the biggest fear with interferon is the potential to generate a “cytokine storm,” but there is “absolutely no evidence of that” from the SARS outbreak in Toronto or in COVID-19 patients. “If anything, the evidence was in the other direction, that we reduce the inflammatory response. Fear of cytokine storm I really think needs to be put to bed once and for all,” Dr. Fish said.
"

Hi AGEOS, welcome back!

Your comment on "a 4BT deposit NE of Los Angeles awaiting a favourable economic climate for development" is clearly a reference to North-South holdings. It's been a mystery to me why nothing ever seemed to come of that. Could you enlarge on what the "favourable economic climate for development" would involve for them to become active?

For anyone unaware :

http://www.northsouth-h.com/projects/north-american-mining-operation-of-pozzolan/

https://www.proactiveinvestors.co.uk/companies/news/919698/keywords-studios-in-strong-position-to-continue-acquisition-strategy-following-100mln-raise-919698.html

This is the results from the IFN-alpha2b trial involving Eleanor Fish which we noted a couple of days ago :

https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full

Results are positive, but it's a small "uncontrolled, exploratory study" which will need a bigger better controlled follow-up if it's to get anywhere.

"Irrespective of these significant limitations, to our knowledge, the findings presented here are the first to suggest therapeutic efficacy in COVID-19 disease of IFN-a2b, an available antiviral intervention. Furthermore, beyond clinical benefit to the individual patient, treatment with IFN-a2b may also benefit public health measures aimed at slowing the tide of this pandemic, in that duration of viral shedding appears shortened."

Yes, it's just an automated system that guesses it's a sell if the trade price was nearer to the Bid than the Ask. Gets it wrong all the time with small mcap shares like this.